Current Report Filing (8-k)
February 08 2022 - 08:58AM
Edgar (US Regulatory)
false000162510100016251012022-02-082022-02-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM
8-K
____________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 8, 2022
____________________
Pulse Biosciences, Inc.
(Exact name of registrant as specified in its charter)
____________________
|
|
|
|
|
|
|
Delaware
|
|
001-37744
|
|
46-5696597
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
3957 Point Eden Way
Hayward,
California
94545
(Address of principal executive offices) (Zip code)
(510)
906-4600
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last
report)
____________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2
below):
|
|
|
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
|
PLSE
|
|
The
Nasdaq
Stock Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
ITEM 8.01. OTHER EVENTS
On
February 8, 2022, Pulse Biosciences, Inc. issued a press release
announcing its receipt of a letter from the U.S. Food and Drug
Administration concerning a recent 510(k) submission by the Company
to expand the current labeling of its CellFX System. A copy of this
press release is attached as Exhibit 99.1 and incorporated herein
by this reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
PULSE BIOSCIENCES, INC.
|
|
|
|
|
|
|
By:
|
/s/ Sandra A. Gardiner
|
|
|
|
Sandra A. Gardiner
Chief Financial Officer, Executive Vice President of Finance and
Administration, and Treasurer
(Principal
Financial and Accounting Officer)
|
Date: February 8, 2022
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2022 to Jun 2022
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jun 2021 to Jun 2022
